Loading…
Fierce Virtual Series: JPM Week 2021 has ended
Back To Schedule
Monday, January 11 • 10:00am - 10:45am
In-Development COVID-19 Therapeutics

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
What are the most promising therapeutics coming up through biopharma's pipelines? How can pharma improve on those therapeutics currently in use under emergency authorizations? What role will combinations play, and which mechanisms of action might pair well together? How many opportunities will be left for therapeutic makers after vaccines take hold? Which companies are looking to treat COVID's long-lasting effects (lung damage, kidney damage etc.) and how?

Moderator
avatar for Amirah Al Idrus

Amirah Al Idrus

Editor, Fierce Biotech

Speakers
avatar for Julie Kim

Julie Kim

President of the Plasma-Derived Therapies Business Unit, Takeda
Julie Kim is the President of the Plasma-Derived Therapies Business Unit for Takeda, responsible for building a sustainable, high growth business focused on meeting the large and growing demand for plasma-derived products, essential for effectively treating patients with a variety... Read More →
avatar for Levi Garraway, M.D., Ph.D.

Levi Garraway, M.D., Ph.D.

Chief Medical Officer, Roche and Genentech
Levi Garraway, M.D., Ph.D., was appointed Chief Medical Officer and Executive Vice President, Head of Global Product Development for Roche and Genentech in October 2019. He leads employees in the Product Development organization across the globe, oversees all aspects of late stage... Read More →
avatar for Ann Leen, Ph.D.

Ann Leen, Ph.D.

Chief Scientific Officer, AlloVir
Dr. Ann Leen is co-founder/CSO at AlloVir. She has seven+ years of industry experience and >20 years of basic and translational science experience in academia. She is based at the Center for Cell and Gene Therapy at Baylor where she serves as Professor, Pediatrics. She has developed... Read More →
avatar for Wendy Holman

Wendy Holman

CEO and Founder, Ridgeback Biotherapeutics
avatar for Karen Flynn

Karen Flynn

Chief Commercial Officer & President, Biologics, Catalent
Karen Flynn was named President, Biologics and Chief Commercial Officer in 2020. Prior to joining Catalent, she served as the Senior Vice President and Chief Commercial Officer of West Pharmaceutical Services, Inc. from 2016 to 2019, having previously served as that company’s President... Read More →


Monday January 11, 2021 10:00am - 10:45am EST